Новости медицины портала Remedium.ru - самая актуальная информация о рынке лекарств и медицинского обеспечения

Опрос для врачей

  1. Пользуетесь ли вы интернетом на работе?

Вход на сайт

Авторизоваться
Логин:
Пароль:
Регистрация
Забыли свой пароль?

Facebook

Вакансии фармкомпанийФармрынок

Реклама




Главная / Врачам

05.02.2018

Пневмоцистная пневмония при ревматических заболеваниях: вопросы профилактики


20. Mecoli CA, Saylor D, Gelber AC, et al. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Clin Exp Rheumatol, 2017, 35(4): 671-673.
21. Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis, 2017, published online November 1.
22. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc, 1996, 71(1): 5-13.
23. Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res, 2011, 63(5): 761-5.
24. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum, 1997, 40(12): 2187-98.
25. Demoruelle MK, Kahr A, Verilhac K, et al. Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care Res, 2013, 65(2): 314-23.
26. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci, 2007 Jun, 52(6): 1481-4.
27. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology, 2008, 47(8): 1256-7.
28. Wolfe RM, Peacock JE. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? Curr Rheumatol Rep, 2017, 19(6): 35. doi: 10.1007/s11926-017-0664-6.
29. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener’s granulomatosis. Am J Respir Crit Care Med, 1995, 151: 795-9.
30. Godeau B, Coutant-Perronne V, Huong DLT, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol, 1994, 21(2): 246-51.
31. Vananuvat P,Suwannalai P,Sungkanuparph S, et al. Primary prophylaxis for pneumocystis jiro vecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum, 2011, 41: 497-502.
32. Zycinska K, Wardyn KA, Zielonka TM, et al. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur J Med Res, 2009, 14: 265-7.
33. Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol, 2010, 37(7): 1416-21.
34. Fillatre P, Decaux O, Jouneau S. et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med, 2014, 127(12): 1242.e11-7.
35. Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int, 2014, 34: 1765-71.
36. Jones RB, Tervaert JWC, Hauser T, et al. Rituxi mab versus cyclophosphamide in ANCA-associ ated renal vasculitis. N Engl J Med, 2010, 363: 211-20.
37. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med, 2013, 369(5): 417-27.
38. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med, 2014, 371(19): 1771-80.
39. Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Investig, 2015, 45(3): 346-68.
40. Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for themanagement of ANCA-associated vasculitis. Ann Rheum Dis, 2016, 75: 1583-94.
41. Chung JB, Armstrong K, Schwartz S, et al. Costeffectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum, 2000, 43(8): 1841-8.
42. Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol, 1992, 19(2): 265-9.
43. Pope J, Jerome D, Fenlon D, et al. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol, 2003, 30: 480-4.
44. Maezawa R, Kurasawa K, Arai S, et al. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases. Mod Rheumatol, 2013, 23: 62-70.
45. Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep, 2014, 16(10): 445. doi: 10.1007/s11926-014-0445-4.
46. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol, 2012, 107(9): 1409-22.
47. Baddley JW, Winthrop KL, Chen L. et al. Nonviral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis, 2014 Nov, 73(11): 1942-8.
48. Dixon WG, Watson K, Lunt M. et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 2006, 54(8): 2368-76.
49. Greenberg JD, Reed G, Kremer JM, et al. Associ ation of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis, 2010 Feb, 69(2): 380-6.
50. Salmon-Ceron D, Tubach F, Lortholary O. et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis, 2011, 70(4): 616-23.
51. Takeuchi T, Tatsuki Y, Nogami Y et al. Post marketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis, 2008, 67(2): 189-94.
52. Koike T, Harigai M, Inokuma S. et al. Postmarke ting surveillance of the safety and effectiveness of etaner cept in Japan. J Rheumatol, 2009, 36(5): 898-906.
53. Komano Y, Tanaka M, Nanki T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol, 2011, 38(7): 1258-64.
54. Beukelman T, Xie F, Baddley JW et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum, 2013, 65(5): 1384-9.
55. Mori S, Sugimoto M. Pneumocystis jirovecii Pneumo nia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations. Clin Med Insights Circ Respir Pulm Med, 2015, 9(Suppl 1): 29-40.
56. Louie GH, Wang Z, Ward MM. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis Rheum, 2010, 62(12): 3826-7.
57. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis, 2014, 58(12): 1649-57.
58. Foocharoen C, Siriphannon Y, Mahakkanukrauh A.et al. Incidence rate and causes of infection in Thai systemic sclerosis patients. Int J Rheum Dis, 2012, 15(3): 277-83.

59. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med, 2006, 354(25): 2655-66.




Ключевые слова: пневмоцистная пневмония, ревматические заболевания, глюкокортикоиды, цитостатики, ко-тримоксазол, профилактика, pneumocystis pneumonia, rheumatic diseases, glucocorticoids, cytostatics, co-trimoxazole, prophylaxis
 

Последние статьи

Мероприятия

     2018
След. год

Пн Вт Ср Чт Пт Сб Вс
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31 1 2 3 4


Подписка


Реклама


Мы в Twitter

Фармацевтам